[{"id":"884c90cc-7b41-4f27-b4c0-809cc02777c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05914376","created_at":"2023-06-22T19:11:48.636Z","updated_at":"2024-07-02T16:35:15.173Z","phase":"Phase 1","brief_title":"Safety of Recombinant Human IL-21 Oncolytic Vaccinia Virus Injection（hV01) in Advanced Tumors","source_id_and_acronym":"NCT05914376","lead_sponsor":"Hangzhou Converd Co., Ltd.","biomarkers":" EGFR • CD8 • IFNG • IL6 • TNFA • CD4 • NCAM1","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • CD8 • IFNG • IL6 • TNFA • CD4 • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hV01"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-03-12"}]